RHYTHM PHARMACEUTICALS, INC. Accumulated Other Comprehensive Income
RHYTHM PHARMACEUTICALS, INC. (RYTM) had Accumulated Other Comprehensive Income of -$912.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-04
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$912.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $444.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$796.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$926.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$912.00K 10-Q · filed 2026-08-04 |
| 2026-03-31 | $444.00K 10-Q · filed 2026-05-05 |
| 2025-12-31 | -$796.00K 10-Q · filed 2026-08-04 |
| 2025-09-30 | -$926.00K 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$2.25M 10-Q · filed 2025-08-05 |
| 2025-03-31 | -$51.00K 10-Q · filed 2025-05-07 |
| 2024-12-31 | -$39.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | -$604.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | -$617.00K 10-Q · filed 2024-08-06 |
| 2024-03-31 | -$181.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $134.00K 10-K · filed 2025-02-28 |
| 2023-09-30 | -$113.00K 10-Q · filed 2023-11-08 |
| 2023-06-30 | -$14.00K 10-Q · filed 2023-08-01 |
| 2023-03-31 | -$6.00K 10-Q · filed 2023-05-02 |
| 2022-12-31 | -$92.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | -$339.00K 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$906.00K 10-Q · filed 2022-08-03 |
| 2022-03-31 | -$629.00K 10-Q · filed 2022-05-03 |
| 2021-12-31 | -$1.00K 10-K · filed 2023-03-01 |
| 2021-09-30 | $21.00K 10-Q · filed 2021-11-02 |
| 2021-06-30 | $21.00K 10-Q · filed 2021-08-03 |
| 2021-03-31 | -$58.00K 10-Q · filed 2021-05-03 |
| 2020-12-31 | $49.00K 10-K · filed 2022-03-01 |
| 2020-09-30 | $238.00K 10-Q · filed 2020-11-02 |
| 2020-06-30 | $630.00K 10-Q · filed 2020-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |